Crucell chronicles

Weekly stock price for Crucell (Euronext:CRXL; CRXL) on Euronext Amsterdam tracked against selected events since 2000. 6/30/00 - IntroGene and U-BiSys merge and change name to CrucellA. 10/27/00 - Raises E144M ($119M) in an IPO on Euronext Amsterdam and NASDAQB. 6/28/01 - Partners with Vaxin to develop two vaccines using CRXL's PER.C6 human cell line production technology and related vaccination technology and Vaxin's EasyVax patch delivery system. The first vaccine will be a rabies vaccine and the second will be chosen by CRXL.C. 8/16/01 - Announces that Centocor, part of Johnson & Johnson (JNJ), will develop and commercialize CRXL's CD46-specific human antibodies for cancerD. 5/16/02 - Enters into a CRADA with the NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine against Ebola virus. The vaccine, which will contain optimized Ebola genes from NIAID, will be based on CRXL's AdVac vector based on adenovirus serotype 35 and will be produced in its PER.C6 human cell line.E. 12/24/02 - Centocor returns all rights to the CD46 target and anti-CD46 antibodies

F. 1/7/04 - Grants Aventis, now part of sanofi-aventis (Euronext:SAN; SNY), an exclusive license to research, develop, manufacture and market cell-based flu vaccines using PER.C6G. 3/11/04 - Acquires ChromaGenics for E4M ($5M) in cash and gains ChromaGenics' STAR gene regulation technology for protein production, including recombinant human antibodiesH. 3/24/04 - Partners with Aeras Global TB Vaccine Foundation to develop vaccines using AdVac vector based on the adenovirus serotype 5 vector and PER.C6I. 6/25/04 - Announces that a MAb discovered with its MAbstract technology and produced on PER.C6 protected ferrets from SARSJ. 4/14/05 - Says it will receive up to E21.4M ($27.6M) to manufacture a PER.C6-based Ebola vaccine for NIAID's Vaccine Research Center K. 5/10/05 - Raises E52.2M ($66.9M) in a private placementL. 7/14/05 - Announces plans to enter its first PER.C6-based protein product into the clinic by YE06. The combination of two human MAbs against rabies was discovered using the MAbstract technology.M. 8/17/05 - Enters into a CRADA with the U.S. Navy's Naval Medical Research Center to construct AdVac-based vaccines against anthrax and plague and test them in non-human primates...